July 23, 2020 / 10:46 AM / 18 days ago

UK-backed firm buys vaccine facility from Benchmark Holdings

FILE PHOTO: A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration taken April 10, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) - A firm backed by the UK government has purchased a vaccine manufacturing facility from healthcare company Benchmark Holdings as the country ramps up efforts to produce potential coronavirus vaccines.

The London-listed company said on Thursday that Cell and Gene Therapy Catapult has bought its vaccine manufacturing facility at Braintree, UK for 16 million pounds ($20.36 million) in cash.

“This new ... centre, alongside crucial investment in skills, will support our efforts to rapidly produce millions of doses of a coronavirus vaccine while ensuring the UK can respond quickly to potential future pandemics,” UK Business Secretary Alok Sharma said in a separate statement.

The deal is part of the UK government’s 100-million-pound investment plan to boost its capacity to rapidly produce COVID-19 vaccines when they are available.

CGT Catapult is supported by Innovate UK.

Reporting by Pushkala Aripaka in Bengaluru; Editing by Saumyadeb Chakrabarty

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below